Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 07-11-2023 | Hyperaldosteronism | Case Report

Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication

Authors: Seiji Hoshi, Akifumi Onagi, Ryo Tanji, Ruriko Honda-Takinami, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Yoshiyuki Kojima

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Patients with bilateral primary aldosteronism (PA) generally are treated with antihypertensive drugs, but optimal treatment for patients with complications due to refractory hypertension has not been established. In this report, we present a case with bilateral PA who presented with persistent hypertension, despite treatment with 6 drugs, and left-dominant heart failure, which was improved after unilateral adrenalectomy.

Case presentation

A 61-year-old man was admitted to our hospital because of severe left-dominant heart failure. His heart rhythm was atrial fibrillation and the left ventricle was diffusely hypertrophic and hypokinetic. Coronary arteries were normal on coronary arteriogram. Primary aldosteronism was suspected based on severe hypokalemia (2.5 mEq/L) and plasma aldosterone concentration (PAC; 1,410 pg/mL). Although computed tomography (CT) showed a single left cortical nodule, adrenal vein sampling (AVS) indicated bilateral PA. Early in the case, heart failure and hyperkalemia in this patient were improved by treatment with a combination of 6 antihypertensive drugs (spironolactone 25 mg/day, eplerenone 100 mg/day, azosemide 60 mg/day, tolvaptan 7.5 mg/day, enalapril 5 mg/day, and bisoprolol fumarate 10 mg/day); however, heart failure relapsed after four months of treatment. We hypothesized that hypertension caused by excess aldosterone was inducing the patient’s heart failure. In order to reduce aldosterone secretory tissue, a laparoscopic adrenalectomy was performed for the left adrenal gland, given the higher level of aldosterone from the left gland compared to the right. Following surgery, the patient’s heart failure was successfully controlled despite the persistence of high PAC. Treatment with anti-hypertensive medications was reduced to two drugs (eplerenone 100 mg/day and bisoprolol fumarate 10 mg/day). In order to elucidate the mechanism of drug resistance, immunohistochemistry (IHC) and real time-polymerase chain reaction (RT-PCR) assays were performed to assess the expression of steroidogenic factor 1 (SF-1), a regulator of steroid synthesis in adrenal tissue. IHC and RT-PCR demonstrated that the expression of SF-1 in this patient (at both the protein and mRNA levels) was higher than that observed in unilateral PA cases that showed good responsivity to drug treatment.

Conclusions

Unilateral adrenalectomy to reduce aldosterone secretory tissue may be useful for patients with drug-refractory, bilateral PA. Elevated expression of SF-1 may be involved in drug resistance in PA.
Literature
1.
go back to reference Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. Resistant Hypertension: detection, evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertens (Dallas Tex: 1979). 2018;72(5):e53–e90. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. Resistant Hypertension: detection, evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertens (Dallas Tex: 1979). 2018;72(5):e53–e90.
2.
go back to reference Dick SM, Queiroz M, Bernardi BL, Dall’Agnol A, Brondani LA, Silveiro SP. Update in diagnosis and management of primary aldosteronism. Clin Chem Lab Med. 2018;56(3):360–72.CrossRefPubMed Dick SM, Queiroz M, Bernardi BL, Dall’Agnol A, Brondani LA, Silveiro SP. Update in diagnosis and management of primary aldosteronism. Clin Chem Lab Med. 2018;56(3):360–72.CrossRefPubMed
3.
go back to reference Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.CrossRefPubMed Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.CrossRefPubMed
5.
go back to reference Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int. 1989;35(3):767–77.CrossRefPubMed Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int. 1989;35(3):767–77.CrossRefPubMed
6.
go back to reference Hall JE, Granger JP, Smith MJ Jr., Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone “escape”. Hypertension (Dallas, Tex: 1979) 1984, 6(2 Pt 2):I183-192. Hall JE, Granger JP, Smith MJ Jr., Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone “escape”. Hypertension (Dallas, Tex: 1979) 1984, 6(2 Pt 2):I183-192.
7.
go back to reference Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with Essential Hypertension: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2018;6(1):41–50.CrossRef Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with Essential Hypertension: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2018;6(1):41–50.CrossRef
8.
go back to reference Savoriti C, Petramala L, Zinnamosca L, Colangelo L, Cilenti G, Formicuccia MC, Marinelli C, Sciomer S, Calvieri C, De Toma G, et al. Primary aldosteronism in a patient who exhibited Heart Failure. J Clin Hypertens (Greenwich Conn). 2012;14(8):566–8.CrossRef Savoriti C, Petramala L, Zinnamosca L, Colangelo L, Cilenti G, Formicuccia MC, Marinelli C, Sciomer S, Calvieri C, De Toma G, et al. Primary aldosteronism in a patient who exhibited Heart Failure. J Clin Hypertens (Greenwich Conn). 2012;14(8):566–8.CrossRef
9.
go back to reference Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009;94(7):2437–45.CrossRefPubMed Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009;94(7):2437–45.CrossRefPubMed
10.
go back to reference Kaneko T, Kojima Y, Umemoto Y, Sasaki S, Hayashi Y, Kohri K. Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma. Horm Res. 2008;70(5):294–9.PubMed Kaneko T, Kojima Y, Umemoto Y, Sasaki S, Hayashi Y, Kohri K. Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma. Horm Res. 2008;70(5):294–9.PubMed
11.
go back to reference Gardiner JR, Shima Y, Morohashi K, Swain A. SF-1 expression during adrenal development and tumourigenesis. Mol Cell Endocrinol. 2012;351(1):12–8.CrossRefPubMed Gardiner JR, Shima Y, Morohashi K, Swain A. SF-1 expression during adrenal development and tumourigenesis. Mol Cell Endocrinol. 2012;351(1):12–8.CrossRefPubMed
12.
go back to reference El-Khairi R, Martinez-Aguayo A, Ferraz-de-Souza B, Lin L, Achermann JC. Role of DAX-1 (NR0B1) and steroidogenic factor-1 (NR5A1) in human adrenal function. Endocr Dev. 2011;20:38–46.CrossRefPubMed El-Khairi R, Martinez-Aguayo A, Ferraz-de-Souza B, Lin L, Achermann JC. Role of DAX-1 (NR0B1) and steroidogenic factor-1 (NR5A1) in human adrenal function. Endocr Dev. 2011;20:38–46.CrossRefPubMed
13.
go back to reference Hu D, Ouyang J, Wu Z, Shi T, Wang B, Ma X, Li H, Wang S, Zhang X. Elementary studies on elevated steroidogenic factor-1 expression in aldosterone-producing adenoma. Urol Oncol. 2012;30(4):457–62.CrossRefPubMed Hu D, Ouyang J, Wu Z, Shi T, Wang B, Ma X, Li H, Wang S, Zhang X. Elementary studies on elevated steroidogenic factor-1 expression in aldosterone-producing adenoma. Urol Oncol. 2012;30(4):457–62.CrossRefPubMed
14.
go back to reference Ouyang J, Hu D, Wang B, Shi T, Ma X, Li H, Wang X, Zhang X. Differential effects of down-regulated steroidogenic factor-1 on basal and angiotensin II-induced aldosterone secretion. J Endocrinol Investig. 2011;34(9):671–5. Ouyang J, Hu D, Wang B, Shi T, Ma X, Li H, Wang X, Zhang X. Differential effects of down-regulated steroidogenic factor-1 on basal and angiotensin II-induced aldosterone secretion. J Endocrinol Investig. 2011;34(9):671–5.
Metadata
Title
Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication
Authors
Seiji Hoshi
Akifumi Onagi
Ryo Tanji
Ruriko Honda-Takinami
Kanako Matsuoka
Junya Hata
Yuichi Sato
Hidenori Akaihata
Masao Kataoka
Soichiro Ogawa
Yoshiyuki Kojima
Publication date
07-11-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01503-2

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue